TII
10.11.2020 13:09:04 CET | Business Wire | Press release
Abu Dhabi has unveiled the Technology Innovation Institute (TII), a pioneering global centre for advanced technology research committed to reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation and advanced technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005653/en/
The institute is the dedicated applied research pillar of the Advanced Technology Research Council (ATRC), which was recently established to set the research and development (R&D) priorities for Abu Dhabi.
It aims to deliver discovery science and breakthrough technologies that have a global impact. It is rapidly breaking new ground at its seven initial dedicated research centres, which each have world-class research facilities.
The initial seven areas of focus are: quantum research; autonomous robotics; cryptography; advanced materials; digital security; directed energy; and secure systems.
His Excellency Faisal Al Bannai, Secretary-General of Advanced Technology Research Council, said the institute would help position Abu Dhabi and the UAE as a global hub for advanced technology research.
HE Faisal said: “The Technology Innovation Institute is a pioneering research centre that develops disruptive and transformative technologies that have practical use-cases and global impact. The institute allows us to push the frontiers of knowledge further than ever before for the benefit of science, society, the economy and the environment.”
Teams of international scientists and researchers joined the institute from around the world within two months of the first board meeting in August 2020. This intellectual community will contribute to building a research and development (R&D) ecosystem in Abu Dhabi and the UAE.
TII will also drive applied research, intellectual property development, and academic and industry partnerships. It has already begun working on more than 25 long-term collaborative projects through partnerships with more than 20 world-leading universities.
Importantly, the institute will have the flexibility to rapidly progress research, with a defined research roadmap, committed long-term funding and the ability to make effective decisions in a fast-paced environment.
TII is one of two pillars under ATRC, which was established in May 2020 to expand the breadth and depth of an already thriving R&D ecosystem in Abu Dhabi. Bringing together cross-disciplinary leaders in research and technology, ATRC is cultivating a collaborative research community, accelerating innovation and discovery and fostering a culture of inquiry.
About Technology Innovation Institute (TII):
Technology Innovation Institute, the dedicated applied research pillar of the Advanced Technology Research Council (ATRC), is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The institute has seven initial dedicated research centres, in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the institute connects an intellectual community and contributes to expanding the R&D ecosystem in Abu Dhabi and the UAE. The institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of a knowledge-based economy.
For more information, visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005653/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom